Tirzepatide (LY3298176) ELISA Kit

Catalog No.

KDK13902

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Tirzepatide has been pre-coated onto a microplate. Standards or samples are premixed with an antibody specific for Tirzepatide and then pipetted into the wells. Tirzepatide (LY3298176) in the sample competitively binds to the antibody specific for Tirzepatide with the pre-coated Tirzepatide. After washing away any unbound substances, HRP conjugated probe is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Tirzepatide (LY3298176) bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Tirzepatide (LY3298176) concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

781.25 - 50,000 ng/mL

Sensitivity

627.48 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	35747.7	6369.1	1655.0	31485.3	9766.8	1645.2
Standard deviation	5671.1	584.5	306.9	6199.2	1602.0	306.4
CV (%)	15.9	9.2	18.5	19.7	16.4	18.6

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.

[Weight reduction with incretin mimetics-Opportunities and risks]., PMID:40514554

[Arthritis secondary to tirzepatide. Case report]., PMID:40513494

Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes., PMID:40512543

Type 2 Diabetes Mellitus Remission, Dream or Reality? A Narrative Review of Current Evidence and Integrated Care Strategies., PMID:40512404

2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology., PMID:40512113

Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity., PMID:40512029

Key takeaways from the updated multidisciplinary European MASLD guidelines., PMID:40510733

Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes., PMID:40510603

Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials., PMID:40510020

The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs., PMID:40507574

Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies., PMID:40507553

Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data., PMID:40503067

Cardiovascular benefits of Tirzepatide: A breakthrough in cardio-metabolic care., PMID:40500849

Tirzepatide: a novel therapeutic approach for Alzheimer's disease., PMID:40498212

The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment., PMID:40497223

Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide., PMID:40491599

Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status., PMID:40491239

Tirzepatide differentially affects body weight in mice and humans., PMID:40490496

Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial., PMID:40490415

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis., PMID:40489581

Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea., PMID:40487675

Tirzepatide Affect Sexual Function in Women: Case Report., PMID:40487373

Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study., PMID:40486301

Review of Article: Wu JY, Tu WL, Yu T, Liao KM, Lin YM. Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients. Diabetes Res Clin Pract. 2025;222:112,083., PMID:40484580

GLP-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate PAD., PMID:40484062

Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United States., PMID:40480878

Tirzepatide Outperforms Semaglutide in Head-to-Head Obesity Trial., PMID:40478570

Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis., PMID:40471293

Diabetic ketoacidosis in a patient with type I diabetes treated with tirzepatide., PMID:40471291

GLP-1-based medications: Mechanisms involved in obesity treatment., PMID:40466247

Tirzepatide for weight reduction in people without diabetes., PMID:40461177

The Short and Sweet on Sodium-Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure., PMID:40458830

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait., PMID:40458827

Dual Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist-Associated Thyroiditis: A Case Report of Thyroid Dysfunction Following Tirzepatide Use., PMID:40458348

Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study., PMID:40456414

Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity., PMID:40452343

An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists., PMID:40447342

Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis., PMID:40444045

Euglycemic Ketoacidosis in a Non-diabetic Patient After Tirzepatide Use: A Cautionary Tale., PMID:40443633

[Glucagon-like peptide 1 agonists : the fourth pillar of nephroprotection in type 2 diabetes]., PMID:40443145

[Nutritional management of type 2 diabetes with GLP-1 and GLP-1/GIP agonists]., PMID:40443143

Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN study., PMID:40437798

Exploring the Protective Effects of Traditional Antidiabetic Medications and Novel Antihyperglycemic Agents in Diabetic Rodent Models., PMID:40430489

The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials., PMID:40430487

The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort., PMID:40426877

Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review., PMID:40422561

Tirzepatide for Obstructive Sleep Apnea: A Novel Therapeutic Promise and the Perioperative Considerations., PMID:40420878

Off-label GLP-1 weight-loss medicine use among online bodybuilders: Folk pharmacology, risk and harm reduction., PMID:40418873

Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy., PMID:40415172

Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System., PMID:40413246

Document Download

Tirzepatide (LY3298176) ELISA Kit.pdf